| 1 |
NCT03276013 |
Not yet recruiting |
Pembrolizumab in Combination With Doxorubicin in Advanced, Recurrent or Metastatic Endometrial Cancer |
|
|
Interventional |
Phase 2 |
- Vall d'Hebron Institute of Oncology
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- PFS rate at 6 months according to RECIST 1.1 criteria
- To determine PFS rate at 6 months according to RECIST 1.1 criteria in the different groups by the genomic-The Cancer Genome Atlas (TCGA) classification; namely POLE, MSI, and Microsatellite Stable (MSS)
- To determine median PFS and ORR according to RECIST 1.1 criteria.
- (and 5 more...)
|
51 |
Female |
18 Years and older (Adult, Senior) |
NCT03276013 |
VHIO17001 |
TOPIC |
January 2018 |
January 2020 |
May 2020 |
September 8, 2017 |
September 8, 2017 |
|
|
| 2 |
NCT02822833 |
Recruiting |
The Role of Indocyanine Green to Identify Sentinel Lymph Node in Uterine Cancer |
|
- Procedure: Sentinel lymph node mapping
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Sensitivity and specificity of sentinel lymph node frozen section
- Unilateral or bilateral sentinel lymph node detection rate by indocyanine green
- Negative and positive predictive values for sentinel lymph node frozen section
|
100 |
Female |
18 Years and older (Adult, Senior) |
NCT02822833 |
04 |
|
July 2016 |
June 2017 |
June 2017 |
July 4, 2016 |
September 13, 2016 |
|
- Ankara University School of Medicine Department of Ob&Gyn
Ankara, Turkey
|
| 3 |
NCT02725268 |
Recruiting |
Phase 2 Study of MLN0128, Combination of MLN0128 With MLN1117, Paclitaxel and Combination of MLN0128 With Paclitaxel in Women With Endometrial Cancer |
|
- Drug: Paclitaxel
- Drug: MLN0128
- Drug: MLN1117
|
Interventional |
Phase 2 |
- Millennium Pharmaceuticals, Inc.
- European Network of Translational Research in Ovarian Cancer - EUTROC
- European Network of Individualized Treatment in Endometrial Cancer - ENITEC
- Takeda
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression Free Survival (PFS)
- Percentage of Participants who Experience at Least One Treatment-emergent Adverse Event (TEAE)
- Overall Survival (OS)
- (and 4 more...)
|
242 |
Female |
18 Years and older (Adult, Senior) |
NCT02725268 |
C31004
U1111-1168-1824
2014-005394-37
02725268 |
|
April 1, 2016 |
February 28, 2019 |
September 30, 2019 |
March 31, 2016 |
April 17, 2018 |
|
- University of Alabama Comprehensive Cancer Center
Birmingham, Alabama, United States - University of Arizona Cancer Center
Phoenix, Arizona, United States - Marin Cancer Care
Greenbrae, California, United States - (and 72 more...)
|
| 4 |
NCT02690259 |
Recruiting |
Sentinel Lymph Node Detection in Endometrial Cancer |
|
- Procedure: Sentinel node procedure
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Detection of sentinel nodes
- Detection of Sentinel nodes
- Detection of Setinel nodes
- (and 2 more...)
|
375 |
Female |
18 Years and older (Adult, Senior) |
NCT02690259 |
RegionSkaneKKLund |
|
June 2014 |
June 2019 |
June 2021 |
February 24, 2016 |
September 5, 2017 |
|
- Department of Gynecology and Obstetrics
Lund, Sweden
|
| 5 |
NCT01820884 |
Recruiting |
The Safety of Ovarian Preservation in Stage IA Endometrial Carcinoma |
|
- Procedure: TH
- Procedure: TH/BSO
- Procedure: BPLND
|
Interventional |
Not Applicable |
- Ding Ma
- Shandong University
- Huazhong University of Science and Technology
- Zhejiang University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease-free survival (DFS)
- Clinical gynecologic endocrine function
- Quality of Life
- Overall Survival (OS)
|
240 |
Female |
18 Years to 50 Years (Adult) |
NCT01820884 |
2012-GYN/EC-02 |
EC-02 |
November 2012 |
December 2017 |
December 2018 |
March 29, 2013 |
October 10, 2017 |
|
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China - Qilu Hospital，Shandong University
Jinan, Shandong, China - Women's Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China
|
| 6 |
NCT01820858 |
Recruiting |
The Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma |
|
- Drug: Paclitaxel
- Drug: Paraplatin (Carboplatin Injection)
- Radiation: Pelvic Radiation
- (and 2 more...)
|
Interventional |
Phase 3 |
- Ding Ma
- Shandong University
- Huazhong University of Science and Technology
- Zhejiang University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease-free survival (DFS)
- Side effect of adjuvant chemotherapy
- Complications of radiotherapy
- (and 2 more...)
|
300 |
Female |
18 Years to 65 Years (Adult) |
NCT01820858 |
2012-GYN/EC-01 |
EC-01 |
November 2012 |
December 2017 |
December 2018 |
March 29, 2013 |
October 10, 2017 |
|
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China - Qilu Hospital，Shandong University
Jinan, Shandong, China - Women's Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China
|
| 7 |
NCT03498924 |
Recruiting
New |
Identification and Characterization of Endometrial Cancer With Specific Tumor Markers in Serum and Endometrial Tissue |
- Endometrial Neoplasm Malignant
|
- Diagnostic Test: Measure of biomarkers in serum and endometrial tissue
|
Observational |
|
- Fundación Investigación Sanitaria en León
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- The proportion of positive H-score of HE4.
- Concentration of HE4 in tissue correlates linearly with HE4 in serum.
- Difference in preoperative serum CA125 levels in cases and controls.
- (and 10 more...)
|
80 |
Female |
18 Years and older (Adult, Senior) |
NCT03498924 |
STUDY17104 |
|
August 1, 2017 |
August 1, 2018 |
August 1, 2020 |
April 17, 2018 |
April 17, 2018 |
|
- Tatiana Cuesta-Guardiola
Leon, Spain
|
| 8 |
NCT03241914 |
Recruiting |
Megestrol Acetate Plus LNG-IUS in Young Women With Early Endometrial Cancer |
- Endometrial Neoplasm Malignant Stage I
|
- Drug: Megestrol Acetate
- Device: Levonorgestrel-releasing Intrauterine System(LNG-IUS)
|
Interventional |
Phase 2
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Pathological response rate
- Pathological response time
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
- (and 3 more...)
|
40 |
Female |
18 Years to 45 Years (Adult) |
NCT03241914 |
2017-30-2 |
|
July 4, 2017 |
July 3, 2020 |
July 3, 2020 |
August 8, 2017 |
October 24, 2017 |
|
- Obstetrics and Gynecology Hospital, Fudan University
Shanghai, Shanghai, China
|
| 9 |
NCT03291275 |
Recruiting |
Survival Outcomes of Uterine Malignancies in Chinese Population |
- Endometrial Neoplasms
- Survival
|
- Other: Follow-up for death and recurrence
|
Observational |
|
- Lei Li
- Peking Union Medical College Hospital
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Overall survival
- Progression-free survival
|
10000 |
Female |
Child, Adult, Senior |
NCT03291275 |
SOUM-1 |
|
September 1, 2017 |
September 1, 2022 |
September 1, 2023 |
September 25, 2017 |
February 8, 2018 |
|
- Lei Li
Beijing, China/Beiing, China
|
| 10 |
NCT03112733 |
Recruiting |
Serum Biomarkers in Diagnosis and Predicting Prognosis of Ovarian Cancers |
- Endometrial Neoplasms
- Ovarian Neoplasms
|
- Diagnostic Test: TFF3, SFRP4, Romo1, NFKB
|
Observational |
|
- Ilker Kahramanoglu
- Istanbul University
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Efficacy of serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-Κb in discrimination of benign and malignant gynecologic disease
- Efficacy of serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-Κb in predicting overall survival and disease-free survival
|
180 |
Female |
18 Years to 70 Years (Adult, Senior) |
NCT03112733 |
83045809-604.01.02
TAB-2017-22506 |
|
April 4, 2017 |
January 2018 |
April 2018 |
April 13, 2017 |
January 29, 2018 |
|
- Istanbul University Cerrahpasa Medical Faculty
Istanbul, Turkey
|
| 11 |
NCT03184350 |
Recruiting |
Adjuvant Protontherapy of Cervical and Endometrial Carcinomas |
- Uterine Cervical Neoplasms
- Endometrial Neoplasms Malignant
|
- Radiation: Adjuvant pelvic proton radiation
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of acute treatment-associated adverse events ≥ grade 3 [Safety and Tolerability]
- clinical symptoms according to the CTC AE v4.0. criteria
- Quality of life of all patients included in the study
- (and 3 more...)
|
25 |
Female |
18 Years to 80 Years (Adult, Senior) |
NCT03184350 |
APROVE |
APROVE |
June 2017 |
June 2019 |
June 2021 |
June 12, 2017 |
June 12, 2017 |
|
- Department of radiation oncology, University Hospital Heidelberg
Heidelberg, Germany
|
| 12 |
NCT03291106 |
Recruiting |
Study of Universal Screening for Lynch Syndrome in Chinese Patients of Endometrial Cancer |
- Colorectal Neoplasms, Hereditary Nonpolyposis
- Endometrial Neoplasms
|
- Diagnostic Test: immunohistochemical staining
- Diagnostic Test: tests of microsatellite instability
- Diagnostic Test: clinical criteria of Lynch syndromes
- Diagnostic Test: sequencing for mismatch repair genes
|
Observational |
|
- Lei Li
- Peking Union Medical College Hospital
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Distribution of Lynch syndromes in endometrial cancer
- Reliability of immunohistochemical staining for screening Lynch syndromes
- Reliability of microsatellite instability for screening Lynch syndromes
- Reliability of clinical criteria for screening Lynch syndromes
|
1500 |
Female |
18 Years and older (Adult, Senior) |
NCT03291106 |
Lynch-PUMCH |
|
September 1, 2017 |
October 1, 2019 |
October 1, 2020 |
September 25, 2017 |
September 25, 2017 |
|
- Lei Li
Beijing, China/Beiing, China
|
| 13 |
NCT00250770 |
Recruiting |
Colony-Stimulating Factor-1 (CSF-1) and Other Cytokines in Human Endometrial Carcinogenesis |
- Uterine Neoplasms
- Endometrial Neoplasms
|
|
Observational |
|
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
|
750 |
Female |
Child, Adult, Senior |
NCT00250770 |
CSF-1 |
|
January 1998 |
January 2022 |
January 2022 |
November 8, 2005 |
May 12, 2016 |
|
- University of New Mexico
Albuquerque, New Mexico, United States
|
| 14 |
NCT03207061 |
Recruiting |
Can 3D Ultrasound be Used as an Alternative to MRI to Assess Myometrial Invasion in Endometrial Cancer? |
- Endometrial Cancer
- Endometrial Neoplasms
- Endometrial Hyperplasia
|
- Diagnostic Test: 3D Ultrasound
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Accuracy of diagnosing myometrial invasion in 3D USS compared to MRI
- Accuracy of predicting lymph node metastasis using 3D USS
|
500 |
Female |
18 Years and older (Adult, Senior) |
NCT03207061 |
16HH3687 3D Ultrasound EC |
|
June 13, 2017 |
December 20, 2018 |
January 20, 2019 |
July 2, 2017 |
January 30, 2018 |
|
- Queen Charlotte and Hammersmith Hospital
London, United Kingdom
|
| 15 |
NCT03207126 |
Recruiting |
Pilot Study: Can Ultrasound Guided Biopsy be Used as an Alternative to Hysteroscopy? |
- Endometrial Cancer
- Endometrial Neoplasms
- Endometrial Hyperplasia
- Endometrial Polyp
|
- Diagnostic Test: Ultrasound guided biopsy
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Accuracy of histological diagnosis using ultrasound guided biopsy.
- Patient satisfaction of Ultrasound guided biopsy
|
50 |
Female |
18 Years and older (Adult, Senior) |
NCT03207126 |
16HH3687 USS guided biopsy EC |
|
June 13, 2017 |
December 20, 2018 |
January 20, 2019 |
July 2, 2017 |
December 22, 2017 |
|
- Queen Charlotte and Hammersmith Hospital
London, United Kingdom
|
| 16 |
NCT03207074 |
Recruiting |
Can the iKnife Distinguish Between Normal and Malignant Endometrial Tissue? |
- Endometrial Neoplasms
- Endometrial Cancer
- Endometrial Hyperplasia
- Endometrial Diseases
|
- Diagnostic Test: iKnife i.e. Rapid Evaporative Ionisation Mass Spectrometry
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Diagnostic ability of iKnife (REIMS) in detection of cancer and pre-cancer in endometrial biopsy specimens
|
50 |
Female |
18 Years and older (Adult, Senior) |
NCT03207074 |
16HH3687 iKnife EC |
|
June 13, 2017 |
June 20, 2019 |
October 20, 2019 |
July 2, 2017 |
December 22, 2017 |
|
- Queen Charlotte and Hammersmith Hospital
London, United Kingdom
|
| 17 |
NCT02494791 |
Recruiting |
Universal Screening for Lynch Syndrome in Women With Endometrial and Non-Serous Ovarian Cancer |
- Lynch Syndrome
- Endometrial Neoplasms
- Ovarian Neoplasms
- Colorectal Neoplasms
|
- Behavioral: Questionnaire, Educational Material
|
Interventional |
Not Applicable |
- University Health Network, Toronto
- Mount Sinai Hospital, Canada
- Sunnybrook Health Sciences Centre
- (and 3 more...)
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Screening
|
- Adherence to screening guidelines (colonoscopy and gynecologic risk-reducing surgery) in participants found to have Lynch Syndrome
- Cost-effectiveness of universal enhanced screening strategy to identify women with Lynch Syndrome and their family members via cascade testing
- Incidence of Lynch Syndrome in an unselected group of women with endometrial and non-serous ovarian cancer
- Discovery of novel genetic mutations and molecular events in unexplained MMR loss (Lynch-like Syndrome)
|
915 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT02494791 |
14-8533CE |
LS2 |
July 2015 |
July 2019 |
July 2025 |
July 10, 2015 |
April 19, 2016 |
|
- University Health Network - Princess Margaret Hospital
Toronto, Ontario, Canada
|
| 18 |
NCT03270995 |
Recruiting |
Cognitive-Existential Group Therapy to Reduce Fear of Cancer Recurrence: A RCT Study |
- Breast Neoplasms
- Ovarian Neoplasms
- Endometrial Neoplasms
- Uterine Cervical Neoplasms
|
- Behavioral: Cognitive Existential Therapy Group 1
- Behavioral: Supportive Therapy Group 2
|
Interventional |
Not Applicable |
- McGill University
- Canadian Cancer Society Research Institute (CCSRI)
- Princess Margaret Hospital, Canada
- (and 2 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Supportive Care
|
- Fear of cancer recurrence inventory
- Cancer-specific distress
- Perceived risk of cancer recurrence
- (and 2 more...)
|
144 |
Female |
18 Years and older (Adult, Senior) |
NCT03270995 |
RCT FCR |
|
October 2014 |
December 1, 2018 |
December 1, 2018 |
September 1, 2017 |
March 22, 2018 |
|
- The Ottawa Hospital
Ottawa, Ontario, Canada - Princess Margaret Hospital
Toronto, Ontario, Canada - Jewish General Hospital
Montreal, Quebec, Canada
|
| 19 |
NCT03489473 |
Not yet recruiting
New |
FESPET Study: Female EStrogen recePtor in Endometrial Cancer Treatment |
|
- Diagnostic Test: 18F-FES PET CT scan
|
Observational |
|
- Radboud University
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- University Medical Center Groningen
- Haukeland University Hospital
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- estrogen uptake on FES PET scan
- Estrogen and Progesterone Receptor expression
|
40 |
Female |
40 Years and older (Adult, Senior) |
NCT03489473 |
FESPET |
FESPET |
June 1, 2018 |
June 1, 2019 |
December 1, 2019 |
April 5, 2018 |
April 5, 2018 |
|
|
| 20 |
NCT03485729 |
Recruiting
New |
ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer |
- Endometrial Cancer Recurrent
|
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
30 |
Female |
18 Years and older (Adult, Senior) |
NCT03485729 |
ONC012 |
|
March 21, 2018 |
March 21, 2020 |
March 21, 2021 |
April 2, 2018 |
April 2, 2018 |
|
- Rutgers, The State University of New Jersey
New Brunswick, New Jersey, United States
|
| 21 |
NCT03469674 |
Recruiting |
PORTEC-4a: Molecular Profile-based Versus Standard Adjuvant Radiotherapy in Endometrial Cancer |
- Endometrial Cancer Stage I
- Endometrial Cancer Stage II
|
- Radiation: Vaginal brachytherapy
- Radiation: External beam radiotherapy
- Other: Observation
|
Interventional |
Not Applicable |
- Leiden University Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Vaginal recurrence
- Adverse events
- Health-related cancer-specific quality of life
- (and 9 more...)
|
500 |
Female |
16 Years and older (Child, Adult, Senior) |
NCT03469674 |
P16.054
UL2011-5336
ISRCTN11659025
NTR5841 |
PORTEC-4a |
June 10, 2016 |
December 2021 |
December 2023 |
March 19, 2018 |
March 19, 2018 |
|
- University Hospital Gent
Gent, Belgium - Academic Medical Center
Amsterdam, Netherlands - NKI / Antoni van Leeuwenhoekhuis
Amsterdam, Netherlands - (and 15 more...)
|
| 22 |
NCT03466788 |
Not yet recruiting |
Impact of Adjuvant Chemotherapy on the Quality of Life of Patients Treated for Stage II / III Endometrial Cancer |
- Endometrial Cancer
- Chemotherapy Effect
- Quality of Life
|
- Other: Self questionnaires of quality of life and living conditions
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Other
|
- The impact in terms of overall quality of life of adjuvant chemotherapy by the QLQ-C30 questionnaire
- Neurotoxicity induced by adjuvant chemotherapy by the CIPN20 questionnaire
- Different domains of quality of life impacted remotely by chemotherapy by the QLQ-C30 questionnaire
|
45 |
Female |
18 Years and older (Adult, Senior) |
NCT03466788 |
EndoQOL |
EndoQOL |
March 2018 |
March 2019 |
September 2019 |
March 15, 2018 |
March 16, 2018 |
|
- Centre François Baclesse
Caen, France - Centre Oscar Lambret
Lille, France - Centre Eugène Marquis
Rennes, France - Centre Henri Becquerel
Rouen, France
|
| 23 |
NCT03456791 |
Recruiting |
Human Epididymis Protein 4 in Endometrial Carcinoma |
|
- Diagnostic Test: Human epididymis protein 4
|
Observational |
|
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Relation between preoperative level of human epididymis protein 4 and surgicopathological staging of endometrial carcinoma
|
84 |
Female |
45 Years to 70 Years (Adult, Senior) |
NCT03456791 |
4 |
|
December 1, 2017 |
June 2018 |
December 2018 |
March 7, 2018 |
March 7, 2018 |
|
- Ain Shams University
Cairo, Egypt
|
| 24 |
NCT03438474 |
Not yet recruiting |
Endometrial Cancer Lymphadenectomy Trial |
- Cancer of Endometrium Stage I
- Cancer of Endometrium Stage II
|
- Procedure: Standard surgical procedure for endometrial cancer
- Procedure: systematic lymphadenectomy (LNE)
|
Interventional |
Not Applicable |
- Philipps University Marburg Medical Center
- German Cancer Aid
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival (OS)
- Disease free survival (DFS)
- Disease specific survival (DSS)
- (and 4 more...)
|
640 |
Female |
18 Years to 75 Years (Adult, Senior) |
NCT03438474 |
AGO-OP.6 KKS 228 |
ECLAT |
March 15, 2018 |
February 15, 2028 |
February 15, 2029 |
February 19, 2018 |
February 20, 2018 |
|
- Kliniken Essen Mitte, Evang. Huyssens Stiftung/Knappschaft GmbH, Gynäkologische Onkologie
Essen, Germany - Klinikum Göttingen, Georg-August-Universität, Universitätsfrauenklinik
Göttingen, Germany
|
| 25 |
NCT03366480 |
Recruiting |
A Study to Assess the Efficacy and Safety of ABTL0812 |
- Endometrial Cancer
- Squamous Cell Lung Cancer
|
- Drug: sodium 2-hydroxylinoleic
|
Interventional |
Phase 1
Phase 2 |
- Ability Pharmaceuticals SL
- Hospital Vall d'Hebron
- Institut Català d'Oncologia
- (and 2 more...)
|
Industry / Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Emergent Adverse Events
- Objective response rate (ORR)
- Progression Free Survival (PFS)
- (and 2 more...)
|
80 |
All |
18 Years and older (Adult, Senior) |
NCT03366480 |
ABT-C5-2016
2016-001352-21 |
Endolung |
December 1, 2016 |
December 14, 2017 |
November 15, 2018 |
December 8, 2017 |
December 13, 2017 |
|
- Abilitypharma
Barcelona, Spain
|
| 26 |
NCT03366051 |
Recruiting |
Sentinel Node Mapping in High Risk Endometrial Cancer |
- Endometrial Cancer
- Lymph Node Metastases
|
- Procedure: Sentinel Node Mapping
- Procedure: Lymphadenectomy
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Recurrence
- Survival
- Early morbidity
- (and 3 more...)
|
162 |
Female |
18 Years to 75 Years (Adult, Senior) |
NCT03366051 |
2.392.088 |
ALICE |
December 20, 2017 |
December 20, 2021 |
December 20, 2024 |
December 8, 2017 |
December 11, 2017 |
|
- AC Camargo Cancer Center
Sao Paulo, SP, Brazil
|
| 27 |
NCT03324958 |
Not yet recruiting |
VIrtual REality Glasses for the Enhancement of Acute BRACHYtherapy Tolerance for Endometrial Cancer Patients. |
|
- Device: Virtual reality Helmet
- Other: No Virtual Reality Helmet
|
Interventional |
Phase 3 |
- Institut de Cancérologie de la Loire
- Gustave Roussy, Cancer Campus, Grand Paris
- Centre Antoine Lacassagne
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Mean pain during brachytherapy applicator installations
- Pain during brachytherapy applicator installations, independently at each fraction
- Mean anxiety during brachytherapy applicator installations
- (and 20 more...)
|
170 |
Female |
18 Years and older (Adult, Senior) |
NCT03324958 |
2017-0501
2017-A01919-44 |
Vire-Brachy |
November 1, 2017 |
May 1, 2019 |
May 1, 2019 |
October 30, 2017 |
October 30, 2017 |
|
- Institut de Cancérologie Lucien Neuwirth
Saint-Priest-en-Jarez, France - Institut Gustave Roussy
Villejuif, France
|
| 28 |
NCT03298100 |
Recruiting |
Risk Scoring Model for Endometrial Cancer |
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Specificity and sensitivity of RHEA scoring mdel
- Variables to increase specificity and sensitivity of the score model
|
100 |
Female |
40 Years and older (Adult, Senior) |
NCT03298100 |
3176af |
Cohort |
September 26, 2017 |
June 30, 2018 |
September 30, 2018 |
September 29, 2017 |
September 29, 2017 |
|
- Ain Shams University Maternity Hospital
Cairo, Egypt
|
| 29 |
NCT03189446 |
Recruiting |
Vaginal Cuff Brachytherapy Followed by Chemotherapy in Endometrial Cancer |
- Endometrial Cancer
- Papillary Serous
- Clear Cell Endometrial Cancer
|
- Radiation: Vaginal Cuff Brachytherapy
- Drug: Carboplatin
- Drug: Paclitaxel
|
Interventional |
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of patients able to complete 6 cycles of treatment
- Number of participants with treatment related adverse events
- Number of participants who recur in radiation field versus distant recurrence
|
50 |
Female |
18 Years to 99 Years (Adult, Senior) |
NCT03189446 |
7964 |
|
October 2, 2017 |
June 1, 2022 |
June 1, 2023 |
June 16, 2017 |
October 31, 2017 |
|
- Stephenson Cancer Center, University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
|
| 30 |
NCT03115593 |
Not yet recruiting |
Compare the Performance of Targeted Biopsy Versus Aspiration Biopsy With a Pipette for the Diagnosis of Endometrial Cancer |
|
- Procedure: Blind biopsy with a pipette
- Procedure: Targeted biopsy using hysteroscopy
|
Interventional |
Not Applicable |
- Brugmann University Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
|
360 |
Female |
Child, Adult, Senior |
NCT03115593 |
CHUB-Hystocor |
|
March 2018 |
March 2020 |
March 2020 |
April 14, 2017 |
January 23, 2018 |
|
- CHU Brugmann
Brussels, Belgium - Hôpitaux Iris Sud - Site Ixelles
Brussels, Belgium - CHR Citadelle
Liege, Belgium - Hôpital Bicêtre
Le Kremlin Bicêtre, France
|
| 31 |
NCT03099499 |
Recruiting |
Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer |
|
|
Interventional |
Phase 2 |
- Fox Chase Cancer Center
- Oncoceutics, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival (PFS) rate at 12 weeks
- Objective Response rate (ORR) as determined by Response Criteria In Solid Tumors (RECIST)1.1 criteria
- Safety profile of ONC201 will be determined by adverse events according to Common terminology criteria for Adverse Events (CTCAE) 4.03
- (and 3 more...)
|
36 |
Female |
18 Years and older (Adult, Senior) |
NCT03099499 |
GYN-106 |
|
June 8, 2017 |
October 1, 2019 |
October 1, 2020 |
April 4, 2017 |
July 14, 2017 |
|
- Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
|
| 32 |
NCT03095664 |
Recruiting |
Effect of a Lifestyle Intervention on Nutritional Status and Prognosis of Endometrial Cancer Survivors |
- Endometrium Cancer
- Life Style
- Obesity
|
- Behavioral: Intervention group
|
Interventional |
Not Applicable |
- Brazilian National Cancer Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival
- Change in Quality of life
- Change in handgrip strength
- (and 11 more...)
|
286 |
Female |
20 Years to 69 Years (Adult, Senior) |
NCT03095664 |
55155116.9.0000.5274 |
|
November 2016 |
November 2023 |
November 2023 |
March 30, 2017 |
April 4, 2017 |
|
- Brazilian National Cancer Institute
Rio de Janeiro, RJ, Brazil
|
| 33 |
NCT03077698 |
Recruiting |
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer |
|
- Drug: Sodium Cridanimod
- Drug: progestin therapy
|
Interventional |
Phase 2 |
- Xenetic Biosciences, Inc.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Tumor assessment
- Objective Response Rate (ORR)
- Progression-free Survival (PFS)
- (and 2 more...)
|
72 |
Female |
18 Years and older (Adult, Senior) |
NCT03077698 |
VX-EC-2-02 |
|
June 14, 2017 |
January 31, 2021 |
January 31, 2021 |
March 13, 2017 |
March 1, 2018 |
|
- Providence St. Joseph Medical Center - Gynecology
Burbank, California, United States - University of California - Irvine Healthcare
Irvine, California, United States - UCLA
Los Angeles, California, United States - (and 17 more...)
|
| 34 |
NCT03024398 |
Not yet recruiting |
Evaluation of the Fluorescent Green of Indocyanine in the Detection of Sentinel Lymph Node in Endometrial Cancer |
- Cancer of the Endometrium
|
|
Observational |
|
- University Hospital, Strasbourg, France
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Detection of sentinel node
|
50 |
Female |
18 Years and older (Adult, Senior) |
NCT03024398 |
6492 |
Sentimetre |
January 2017 |
January 2019 |
January 2019 |
January 18, 2017 |
January 18, 2017 |
|
- Service de gynécologie-obstétrique - Hôpital de Hautepierre
Strasbourg, France
|
| 35 |
NCT03016338 |
Recruiting |
Study of Niraparib in Recurrent Endometrial Cancer |
|
|
Interventional |
Phase 2 |
- University Health Network, Toronto
- Tesaro, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Clinical benefit rate
- Number of side effects
- Overall response rate
- (and 3 more...)
|
44 |
Female |
18 Years and older (Adult, Senior) |
NCT03016338 |
NEC |
|
November 6, 2017 |
March 2022 |
September 2022 |
January 10, 2017 |
March 23, 2018 |
|
- Tom Baker Cancer Centre
Calgary, Alberta, Canada - Cross Cancer Institute
Edmonton, Alberta, Canada - British Columbia Cancer Agency
Vancouver, Alberta, Canada - (and 6 more...)
|
| 36 |
NCT02987881 |
Recruiting |
Endometrial Cancer Diet and Exercise |
- Early Stage Endometrial Cancer
|
- Behavioral: Home-based aerobic exercise and nutritional counseling
|
Interventional |
Not Applicable |
- Duke University
- Duke Cancer Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Feasibility as measured by adherence to weekly walking sessions
- Safety as measured by the type and prevalence of adverse events during study-related assessments
- change in cardiorespiratory fitness and CVD risk profile as measured by VO2peak
- (and 5 more...)
|
15 |
Female |
18 Years and older (Adult, Senior) |
NCT02987881 |
Pro00074542 |
|
February 1, 2017 |
July 2019 |
July 2019 |
December 9, 2016 |
October 26, 2017 |
|
- Duke University Medical Center
Durham, North Carolina, United States
|
| 37 |
NCT02912572 |
Recruiting |
Study of Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer |
- Metastatic Endometrial Cancer
|
|
Interventional |
Phase 2 |
- Dana-Farber Cancer Institute
- Pfizer
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Activity Of Avelumab In Patients With Recurrent Or Persistent Endometrial Cancer
- Duration of Progression Free Survival as Assessed by RECIST 1.1
- Duration of Overall Survival
- (and 2 more...)
|
70 |
Female |
18 Years and older (Adult, Senior) |
NCT02912572 |
16-322 |
|
November 14, 2016 |
April 2020 |
April 2024 |
September 23, 2016 |
June 7, 2017 |
|
- University of Chicago
Chicago, Illinois, United States - Massachusetts General Hospital
Boston, Massachusetts, United States - Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States - Dana Farber Cancer Institute
Boston, Massachusetts, United States
|
| 38 |
NCT02899793 |
Recruiting |
Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer |
- Recurrent Endometrial Cancer
|
|
Interventional |
Phase 2 |
- Yale University
- Merck Sharp & Dohme Corp.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Frequency of objective tumor response as assessed by RECIST 1.1
- Frequency and severity of adverse events as assessed by CTCAE v4
- Duration of progression-free survival (PFS)
- Overall survival (OS)
|
25 |
Female |
18 Years to 100 Years (Adult, Senior) |
NCT02899793 |
1605017712 |
|
September 2016 |
June 2018 |
June 2018 |
September 14, 2016 |
October 9, 2017 |
|
- Yale New Haven Hospital
New Haven, Connecticut, United States
|
| 39 |
NCT02834988 |
Recruiting |
Sentinel Lymph Node Dissection (SLND) in Patients With Apparent Early Stage Endometrial Cancer |
|
- Procedure: Sentinel Lymph Node Dissection
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- SLND Positivity Rate in Study Participants
- Rate of NPV and FNPV of the SLND Procedure in Study Participants Who Undergo Partial or Full Lymphadenectomy.
- Proportion of Types of Lymph Node Metastases Described by SLND in Study Participants
- (and 2 more...)
|
1700 |
Female |
18 Years and older (Adult, Senior) |
NCT02834988 |
20151012 |
|
July 28, 2016 |
January 2020 |
June 2020 |
July 15, 2016 |
December 7, 2017 |
|
- University of Miami
Miami, Florida, United States
|
| 40 |
NCT02826291 |
Recruiting |
SLNM in Endometrial Cancer Combined With OSNA |
|
|
Observational |
|
- Charles University, Czech Republic
- University Hospital Pilsen
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- number of CK 19 copies detected by OSNA
|
31 |
Female |
18 Years and older (Adult, Senior) |
NCT02826291 |
OSNA-EC-01 |
SLNM/OSNA |
March 2016 |
December 2017 |
December 2017 |
July 7, 2016 |
February 1, 2017 |
|
- Faculty Hospital in Pilsen
Pilsen, Czech Republic
|
| 41 |
NCT02774395 |
Not yet recruiting |
Endometrial Cancer and Fractalkine-receptor Axis of Fractalkine |
|
|
Observational |
|
- Centre Hospitalier Universitaire de Nice
- Centre National de la Recherche Scientifique, France
|
Other |
- Time Perspective: Prospective
|
- expression rate of FKN
- expression rate of CX3CR1
- expression rate of the couple FKN / CX3CR1
- (and 4 more...)
|
40 |
Female |
18 Years and older (Adult, Senior) |
NCT02774395 |
15-AOI-09 |
|
May 2016 |
May 2018 |
January 2019 |
May 17, 2016 |
May 17, 2016 |
|
|
| 42 |
NCT02767362 |
Recruiting |
A Pre-Op Window Study Evaluating Anti-Proliferative Effects of Atorvastatin on the Endometrium |
|
|
Interventional |
Early Phase 1 |
- UNC Lineberger Comprehensive Cancer Center
- Wilma Williams Education and Clinical Research for Endometrial Cancer Award
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Absolute difference score
|
24 |
Female |
18 Years to 75 Years (Adult, Senior) |
NCT02767362 |
LCCC 1514 |
|
November 2015 |
November 2018 |
November 2019 |
May 10, 2016 |
September 13, 2017 |
|
- University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, United States
|
| 43 |
NCT02762214 |
Recruiting |
Role of Uterine Manipulator in Hysterectomy - Ro.Man.HY |
|
- Device: Clermont-Ferrand Uterine Manipulator
- Other: No uterine Manipulator
|
Interventional |
Phase 3 |
- Catholic University of the Sacred Heart
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Upstaging rate
- Complications
- Blood Loss
- (and 4 more...)
|
154 |
Female |
18 Years to 80 Years (Adult, Senior) |
NCT02762214 |
RoManHy |
RoManHy |
October 2015 |
October 2016 |
October 2017 |
May 4, 2016 |
May 4, 2016 |
|
- Division of Oncologic Gynecology, Fondazione Policlinico Gemelli
Rome, Italy
|
| 44 |
NCT02755844 |
Not yet recruiting |
Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Endometrial Cancer Patients |
- Recurrent Endometrial Cancer
|
- Drug: Olaparib
- Drug: metformin
- Drug: metronomic cyclophosphamide
|
Interventional |
Phase 1
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Recommended phase 2 trial (RP2D) dose of olaparib combined to metronomic cyclophosphamide and metformin
- Efficacy of olaparib combined to metronomic cyclophosphamide and metformin
- Number of patients with adverse events relative to the study treatment olaparib combined to metronomic cyclophosphamide and metformin
- (and 3 more...)
|
36 |
Female |
18 Years to 81 Years (Adult, Senior) |
NCT02755844 |
69HCL15_0321 |
ENDOLA |
April 2016 |
April 2018 |
November 2019 |
April 29, 2016 |
April 29, 2016 |
|
- Centre Hospitalier Lyon Sud
Pierre Benite, France
|
| 45 |
NCT02730429 |
Recruiting |
Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer |
|
- Drug: Palbociclib/placebo
- Drug: Letrozole
|
Interventional |
Phase 2 |
- Nordic Society for Gynaecologic Oncology
- European Network of Gynaecological Oncological Trial Groups (ENGOT)
- GCIG
- (and 3 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Progression-Free Survival (PFS). Increase in median PFS in experimental arm versus comparator arm
- PFS of patients in the sub-populations as described under stratification factors. Increase in median PFS in experimental arm versus comparator arm
- Overall Response Rate (ORR) according to RECIST
- (and 8 more...)
|
78 |
Female |
18 Years and older (Adult, Senior) |
NCT02730429 |
ENGOT-EN3-NSGO/PALEO |
|
February 15, 2017 |
December 2020 |
December 2022 |
April 6, 2016 |
April 4, 2017 |
|
- NSGO
Copenhagen, Sjaelland, Denmark
|
| 46 |
NCT02730416 |
Recruiting |
Combination Chemotherapy With Nintedanib / Placebo in Endometrial Cancer |
|
- Drug: Nintedanib or Placebo; Carboplatin, Paclitaxel
|
Interventional |
Phase 2 |
- Nordic Society for Gynaecologic Oncology
- North Eastern Germany Society of Gynaecologic Oncology
- Belgian Gynaecological Oncology Group
- ARCAGY/ GINECO GROUP
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- PFS: Difference in months of Median Progression-Free Survival in experimental arm versus comparator arm
- PFS in the sub-populations as described under stratification factors
- PFS after consecutive treatment (PFS2). To be measured (in months) and reported
- (and 9 more...)
|
148 |
Female |
18 Years and older (Adult, Senior) |
NCT02730416 |
ENGOT-EN1/FANDANGO |
|
November 2016 |
July 2021 |
July 2022 |
April 6, 2016 |
March 30, 2017 |
|
- NSGO
Copenhagen, Sjaelland, Denmark
|
| 47 |
NCT02684318 |
Recruiting |
Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors |
- Advanced Cancer
- Ovarian Cancer
- Endometrial Cancer
- Breast Cancer
|
|
Interventional |
Phase 1
Phase 2 |
- Poveda, Andrés, M.D.
- AstraZeneca
- PharmaMar
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dose limiting toxicity
- Maximum tolerated dose
- Efficacy in terms of Tumor Response Rate according to RECIST 1.1 criteria.
- (and 5 more...)
|
100 |
All |
18 Years and older (Adult, Senior) |
NCT02684318 |
POLA/ACOG1401 |
|
July 2015 |
July 2019 |
October 2019 |
February 18, 2016 |
June 22, 2017 |
|
- Hospital Reina Sofía
Córdoba, Andalucía, Spain - Hospital Marqués de Valdecilla
Santander, Cantabria, Spain - Hospital Universitario Vall d'Hebron
Barcelona, Spain - (and 3 more...)
|
| 48 |
NCT02684227 |
Recruiting |
Enzalutamide in Combination With Carboplatin and Paclitaxel in Endometrial Cancer |
|
- Drug: Enzalutamide
- Drug: Carboplatin
- Drug: Paclitaxel
|
Interventional |
Phase 2 |
- M.D. Anderson Cancer Center
- Astellas Pharma Inc
- Medivation, Inc.
- National Comprehensive Cancer Network
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (MTD) of Enzalutamide, in Combination with Paclitaxel and Carboplatin in Previously Untreated Participants with Advanced and Recurrent Endometrioid Endometrial Cancer
- Objective Tumor Response of Enzalutamide, in Combination with Paclitaxel and Carboplatin in Previously Untreated Participants with Advanced and Recurrent Endometrioid Endometrial Cancer
|
69 |
Female |
18 Years and older (Adult, Senior) |
NCT02684227 |
2015-0723
NCI-2016-00562 |
|
August 2016 |
August 2019 |
August 2020 |
February 17, 2016 |
March 21, 2018 |
|
- MD Anderson Cancer Center - Memorial City Regional Care Center
Houston, Texas, United States - University of Texas MD Anderson Cancer Center
Houston, Texas, United States - The Woman's Hospital of Houston
Houston, Texas, United States - (and 4 more...)
|
| 49 |
NCT02665962 |
Recruiting |
Evaluating the Effect of Perioperative Caloric Restriction Program on Perioperative Outcomes in Patients With Obesity and Endometrial Cancer |
|
- Other: Perioperative Caloric Restriction Program
|
Interventional |
Not Applicable |
- Abramson Cancer Center of the University of Pennsylvania
|
Other |
- Intervention Model: Single Group Assignment
|
- Number of completed perioperative caloric restriction program in obese newly diagnosed endometrial cancer patients
|
20 |
Female |
18 Years and older (Adult, Senior) |
NCT02665962 |
UPCC 09815 |
|
July 2015 |
July 2017 |
|
January 28, 2016 |
September 26, 2016 |
|
- Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
|
| 50 |
NCT02658565 |
Recruiting |
Selective Surgical Staging for the Treatment of Endometrial Cancer Based on Intraoperative Consultation |
|
- Procedure: Lymphadenectomy
|
Interventional |
Not Applicable |
- Frederick R. Ueland, M.D.
- University of Kentucky
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Recurrence-free survival
- Progression-free survival
- Disease-specific Survival
- (and 3 more...)
|
400 |
Female |
18 Years to 100 Years (Adult, Senior) |
NCT02658565 |
MCC-15-GYN-150 |
|
January 2016 |
December 2019 |
December 2024 |
January 20, 2016 |
January 16, 2018 |
|
- University of Kentucky
Lexington, Kentucky, United States
|
Create an RSS feed from your search for:
Download the search results for: